Efficacy of mesalazine to prevent relapse in paediatric crohns disease
| ISRCTN | ISRCTN84003996 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN84003996 |
| Secondary identifying numbers | Etude Pentacomp/90/91 |
- Submission date
- 13/02/2008
- Registration date
- 10/03/2008
- Last edited
- 10/03/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English Summary
Not provided at time of registration
Contact information
Prof Jean Pierre Cezard
Scientific
Scientific
Hopital Robert Debré 48 Bd Sérurier
Paris
75019
France
| Phone | +33 (0)1 40 03 23 62 |
|---|---|
| jean-pierre.cezard@rdb.aphp.fr |
Study information
| Study design | A multicentric, double-blind, randomised, placebo-controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Scientific title | Prevention of relapse by mesalazine (Pentasa®) in paediatric crohn's disease: a multicentric double-blind randomised placebo-controlled trial |
| Study hypothesis | The trials primary objective was to compare the efficacy of mesalazine (Pentasa®, Ferring) versus placebo in maintaining remission in paediatric crohn's disease (CD) patients, when used after the successful treatment of an acute episode with either medication alone or parenteral/enteral nutrition techniques combined or not with medication. |
| Ethics approval(s) | Ethcis approval received from the Ethics Committee of Paris VII on the 10th January 1991 (ref: Etude Pentacomp/90/01). |
| Condition | Paediatric crohn's disease |
| Intervention | At inclusion, patients were randomised per stratum, within each centre, using random permuted two to four sized-blocks (each centre did not know the size of their own block), to the following: 1. 50 mg/kg/day mesalazine dose 2. Placebo (identical tablets) This was taken over a one-year period. Patients were monitored every three months over a one-year period or until endpoint. The study treatment was initiated either one week after the interruption of parenteral or enteral nutrition, or at the end of a sulfalazine or metronidazole treatment, or if the prednisone dose during the steroid weaning period was below 0.2 mg/kg. After the study treatment began, only antispasmodic and antidiarrhoeal agents, as well as sedatives were to be given as possible additional medications. Following the recruitment of 57 children from 1991 to 1993, trial results showed a trend favouring mesalazine. Recruitment was consequently resumed from 1996 to 1999. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Mesalazine (Pentasa®) |
| Primary outcome measure | 1. Clinical relapse (HB score greater than or equal to 5, if confirmed within two weeks) 2. Surgery for an acute complication of CD Primary and secondary outcomes were measured either at one year of follow up with a medical visit every three months or when the primary or secondary outcomes occur during the one year follow up. |
| Secondary outcome measures | Treatment failure, defined as: 1. Relapse 2. Failure of steroid withdrawal (weaning failure) 3. Side-effects intolerance requiring treatment discontinuation 4. Worsening or aggravation of patient status requiring treatment interruption 5. Initiation of a new treatment as decided by the clinician Primary and secondary outcomes were measured either at one year of follow up with a medical visit every three months or when the primary or secondary outcomes occur during the one year follow up. |
| Overall study start date | 01/01/1991 |
| Overall study end date | 01/01/1998 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Child |
| Upper age limit | 18 Years |
| Sex | Both |
| Target number of participants | 60, extended to 120 |
| Participant inclusion criteria | 1. Children less than 18 years old, either sex 2. Diagnosed with crohns disease before the age of 16 by means of clinical, radiological, endoscopic and histological data 3. Had to be in an active phase defined by: 3.1. A Harvey Bradshaw score (HB) greater than or equal to 5, and 3.2. An erythrocyte sedimentation rate (ESR) greater than or equal to 25 mm at hour one 4. All lesion localisations, except exclusive anorectal localisation, were included, providing patients lesion extension had been assessed within two years prior to inclusion After flare-up treatment, inclusion criteria were as follows: 1. Patients in clinical remission within six months following flare-up treatment initiation at pre-inclusion 2. An HB score under 5 3. An ESR under 25 mm 4. Normal hepatic and renal functions |
| Participant exclusion criteria | 1. Flare-up had been treated with mesalazine or had required immuno-suppressors 2. Patients with known hypersensitivity to salicylate 3. Patients whose flare-up had occurred at pre-inclusion when on a 5-aminosalicylic acid (5-ASA) dose greater than 50 mg/kg/day for over two months |
| Recruitment start date | 01/01/1991 |
| Recruitment end date | 01/01/1998 |
Locations
Countries of recruitment
- France
- Switzerland
Study participating centre
Hopital Robert Debré 48 Bd Sérurier
Paris
75019
France
75019
France
Sponsor information
Ferring SA (France)
Industry
Industry
7 rue Jean Baptiste Clément
Gentilly
94250
France
"ROR" |
https://ror.org/03vrwsp35 |
|---|
Funders
Funder type
Industry
Ferring SA (France)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
